Revalia Bio

Revalia Bio is a private, pre-revenue platform company founded in 2020 and based in Cambridge, USA. It has developed a proprietary infrastructure to conduct experiments on donated, transplant-declined human organs maintained via perfusion technology, creating a new translational research paradigm it terms Human Data Trials. The platform is designed to provide biopharma partners with earlier, more predictive human data to improve target validation, preclinical research, and clinical trial design, thereby reducing late-stage failures and R&D costs. The company targets the oncology and immunology sectors and is backed by a team with deep expertise in organ research, operations, and technology.

Integrated platform for Human Data Trials, comprising an Organ Access Network for ethical sourcing of transplant-declined human organs, normothermic perfusion technology to maintain organ viability, and a data/software backbone to design experiments and analyze multi-omic readouts.

Revalia operates in a niche but competitive space. Direct competitors include other companies working with human organ perfusion for research (e.g., some academic spin-offs). Indirect competitors include providers of advanced preclinical models like organ-on-a-chip companies (e.g., Emulate), complex in vitro systems, and CROs offering specialized animal or tissue-based studies. Revalia's key differentiator is its integrated, end-to-end platform focused specifically on intact human organs.